Peptidos inmunomoduladores: de LL-37 a Thymosin Alpha-1

Introduction: Peptides at the Frontline of Immune Defense

The immune system is fundamentally a peptide-driven enterprise. From the antimicrobial peptides that form the first line of innate defense to the cytokines and chemokines that orchestrate adaptive immune responses, peptide signaling molecules are the operational language of immunity. It is no surprise, then, that peptide-based approaches to immune modulation have become a major focus of biomedical research.

Immune-modulating peptides can be broadly categorized by their primary mechanism of action: direct antimicrobial activity (killing or inhibiting pathogens), immunostimulation (enhancing the activity of immune cells), immunoregulation (balancing immune responses to prevent excessive inflammation), and tissue repair (promoting healing and recovery after immune-mediated tissue damage). Many peptides, however, exhibit activity across multiple categories, reflecting the deeply interconnected nature of immune defense and tissue homeostasis.

This article provides a comprehensive review of seven immune-modulating peptides that have garnered significant research interest: LL-37 (cathelicidin), Thymosin Alpha-1, ARA-290 (Cibinetide), Thymalin, Thymagen, Crystagen, and Vilon. For each compound, we examine its origins, proposed mechanisms, research evidence, and clinical status. This review is for educational purposes only and does not constitute medical advice.

LL-37 / Cathelicidin: The Human Antimicrobial Peptide

Origins and Structure

LL-37 is the only human member of the cathelicidin family of antimicrobial peptides, a class of innate immune defense molecules found across vertebrate species. The name "LL-37" derives from its two N-terminal leucine residues and its total length of 37 amino acids. It is produced as a precursor protein called hCAP-18 (human cationic antimicrobial protein-18), which is cleaved by the protease proteinase 3 to release the active LL-37 peptide.

LL-37 is expressed by a wide variety of cell types, including neutrophils (which store large quantities in secondary granules), macrophages, epithelial cells of the skin, respiratory tract, and gastrointestinal tract, mast cells, and various other immune and barrier cells. Its expression can be constitutive or induced by infection, inflammation, and notably by vitamin D signaling — a connection that has generated significant research interest regarding the role of vitamin D in immune defense.

Structurally, LL-37 adopts an amphipathic alpha-helical conformation in membrane-mimicking environments. This amphipathicity — having both hydrophobic and hydrophilic faces — is fundamental to its ability to interact with and disrupt biological membranes, which underlies its direct antimicrobial activity.

Direct Antimicrobial Activity

LL-37 possesses broad-spectrum antimicrobial activity against bacteria, viruses, and fungi. The primary mechanism of bactericidal activity involves electrostatic attraction of the cationic peptide to the anionic surfaces of bacterial membranes, followed by membrane insertion and disruption. Several models have been proposed for how LL-37 disrupts bacterial membranes:

• Barrel-Stave Model: LL-37 molecules insert vertically into the membrane, forming transmembrane pores lined by the peptide's hydrophilic faces.
• Toroidal Pore Model: LL-37 molecules induce the bacterial membrane lipids to curve inward, forming pores in which both peptide molecules and lipid headgroups line the pore channel.
• Carpet Model: LL-37 molecules accumulate on the membrane surface at high local concentrations, eventually causing membrane solubilization and disintegration in a detergent-like manner.

The selectivity of LL-37 for microbial over mammalian membranes arises from fundamental differences in membrane composition: bacterial membranes are enriched in negatively charged phospholipids (phosphatidylglycerol, cardiolipin), while mammalian cell membranes have their anionic lipids (phosphatidylserine) sequestered on the inner leaflet and are enriched in cholesterol, which stabilizes the membrane against peptide disruption.

LL-37 also exhibits antiviral activity through several proposed mechanisms, including direct virion disruption, interference with viral attachment and entry, and modulation of host cell antiviral responses. Antifungal activity has been demonstrated against Candida species and other pathogenic fungi, again primarily through membrane disruption mechanisms.

Immunomodulatory Functions

Beyond direct microbial killing, LL-37 functions as a sophisticated immune signaling molecule with diverse immunomodulatory effects:

• Chemotactic Activity: LL-37 acts as a chemoattractant for neutrophils, monocytes, mast cells, and T cells, recruiting immune cells to sites of infection and tissue damage. This chemotactic activity is mediated in part through the formyl peptide receptor-like 1 (FPRL1/FPR2), a G-protein coupled receptor.
• Dendritic Cell Modulation: LL-37 influences dendritic cell differentiation and maturation, promoting the development of Th1-type immune responses. It can also act as an adjuvant, enhancing antigen presentation and adaptive immune activation.
• Cytokine Modulation: LL-37 modulates the production of various cytokines and chemokines by immune cells. Interestingly, its effects can be context-dependent: it may enhance certain pro-inflammatory responses during infection while dampening excessive inflammation in sterile tissue damage scenarios.
• Anti-Endotoxin Activity: LL-37 can bind and neutralize lipopolysaccharide (LPS), the major endotoxin of Gram-negative bacteria. This anti-endotoxin activity could be relevant to preventing sepsis and reducing inflammation driven by bacterial products.
• Mast Cell Activation: LL-37 can activate mast cells through MRGPRX2 (Mas-related G protein-coupled receptor X2), triggering degranulation and the release of histamine and other inflammatory mediators. This effect connects antimicrobial peptide biology to allergic and inflammatory pathways.

Wound Healing and Tissue Repair

LL-37 has been investigated for its role in wound healing, with research demonstrating multiple mechanisms that promote tissue repair:

• Angiogenesis: LL-37 promotes the formation of new blood vessels, a critical process in wound healing. It acts directly on endothelial cells through FPRL1, stimulating proliferation, migration, and tube formation.
• Re-Epithelialization: LL-37 stimulates keratinocyte migration and proliferation, promoting the closure of epithelial wounds. This effect is mediated through epidermal growth factor receptor (EGFR) transactivation.
• Fibroblast Function: Research has shown that LL-37 can influence fibroblast behavior, promoting the deposition of extracellular matrix components needed for tissue repair.

Biofilm Disruption

A particularly significant area of LL-37 research involves its effects on bacterial biofilms — structured communities of bacteria encased in a self-produced extracellular matrix that are highly resistant to conventional antibiotics. LL-37 has been shown to:

• Prevent initial biofilm formation on surfaces at sub-inhibitory concentrations
• Disrupt established biofilms by interfering with quorum sensing (bacterial communication) pathways
• Enhance the efficacy of conventional antibiotics against biofilm-embedded bacteria by disrupting the protective matrix

This anti-biofilm activity is of significant research interest given the role of biofilms in chronic infections, medical device infections, and antibiotic resistance.

Research Status and Therapeutic Development

LL-37 and its derivatives are being investigated for numerous potential therapeutic applications, including wound healing, antimicrobial therapy (particularly against antibiotic-resistant organisms), anti-biofilm treatments, and immune modulation. Several synthetic analogs and fragments of LL-37 are in various stages of preclinical and clinical development.

Challenges in therapeutic development include the high production cost of synthetic LL-37, potential cytotoxicity at high concentrations, susceptibility to degradation by endogenous proteases, and the complexity of its immunomodulatory effects (which can be pro-inflammatory in some contexts). Research into formulation strategies, structural modifications for enhanced stability, and targeted delivery systems is ongoing.

Thymosin Alpha-1: A Thymic Peptide for Immune Activation

Origins and Structure

Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a partially purified extract of calf thymus glands prepared by Dr. Allan Goldstein and colleagues at the George Washington University in the 1970s. The thymus gland is the primary lymphoid organ responsible for T cell maturation and education, and the search for thymic hormones that might recapitulate the thymus's immunological functions was a major research endeavor of the 1970s and 1980s.

Ta1 is acetylated at its N-terminus and has a molecular weight of approximately 3,108 daltons. The sequence is highly conserved across mammalian species, suggesting important biological functions. In vivo, Ta1 is believed to be produced by thymic epithelial cells and to play a role in T cell development and maturation, though the precise physiological role of the endogenous peptide continues to be investigated.

Mechanism of Action

Ta1's immunomodulatory mechanism involves multiple arms of the immune system:

• Dendritic Cell Activation: Ta1 has been shown to activate dendritic cells, the professional antigen-presenting cells that bridge innate and adaptive immunity. It promotes dendritic cell maturation, enhances antigen presentation, and stimulates the production of cytokines that drive Th1-type immune responses. Research has demonstrated that Ta1 signals through Toll-like receptors (TLR2 and TLR9) on dendritic cells, engaging pathways normally activated by pathogen-associated molecular patterns.
• T Cell Function: Ta1 promotes the differentiation and activation of T lymphocytes, including CD4+ helper T cells and CD8+ cytotoxic T cells. It has been shown to increase the expression of T cell markers (CD2, CD3, CD4, CD8) and to enhance T cell proliferation in response to mitogens and antigens. In immunocompromised states, Ta1 may help restore T cell numbers and function.
• Natural Killer Cell Activation: Research has demonstrated that Ta1 can enhance the cytotoxic activity of natural killer (NK) cells, innate immune lymphocytes that play critical roles in antiviral defense and tumor immunosurveillance. Ta1-activated NK cells show increased expression of activating receptors and enhanced killing of target cells.
• Cytokine Modulation: Ta1 influences the cytokine milieu, promoting the production of Th1 cytokines (interferon-gamma, interleukin-2) while potentially modulating Th2 cytokine production. This Th1-skewing effect is relevant to its proposed roles in antiviral and antitumor immunity.
• Macrophage Activation: Ta1 enhances macrophage function, including phagocytic activity, antigen processing, and cytokine production. These effects contribute to both the innate immune response and the initiation of adaptive immunity.

Clinical Research and Regulatory Status

Thymosin Alpha-1 has one of the most extensive clinical research profiles of any immunomodulatory peptide, with studies spanning multiple therapeutic areas:

Hepatitis B

Ta1 received FDA orphan drug designation for the treatment of chronic hepatitis B, and multiple clinical trials have investigated its efficacy in this indication. Studies have reported that Ta1 treatment can increase the rates of HBeAg seroconversion and viral suppression in chronic hepatitis B patients, with effects sometimes becoming apparent after treatment completion, suggesting that Ta1 works by restoring immune control rather than directly inhibiting viral replication. Meta-analyses of hepatitis B clinical trials have generally supported the efficacy of Ta1, particularly in combination with interferon-alpha.

Cancer Immunotherapy

Ta1 has been studied as an immunoadjuvant in various cancer types, including hepatocellular carcinoma, non-small cell lung cancer, melanoma, and other malignancies. The rationale is that Ta1 can enhance the immune system's ability to recognize and eliminate tumor cells, either as a standalone treatment or in combination with other immunotherapies, chemotherapy, or radiation. Clinical studies have reported improvements in immune parameters and, in some cases, survival benefits, though the evidence varies by cancer type and study design.

Infectious Diseases

Beyond hepatitis B, Ta1 has been investigated in hepatitis C, HIV infection, and various other infectious diseases. Its ability to enhance cellular immunity makes it a candidate for adjunctive therapy in infections where T cell function is compromised.

Vaccine Enhancement

Ta1 has been studied as a vaccine adjuvant, with research suggesting it can enhance antibody responses and cell-mediated immunity in populations with poor vaccine responsiveness, including elderly individuals and immunocompromised patients.

Global Regulatory Status

Thymosin Alpha-1 (marketed as Zadaxin) has been approved for clinical use in over 35 countries, primarily for the treatment of hepatitis B and as an immune modulator. Approved countries include many in Asia, Europe, and Latin America. However, it has not received FDA approval in the United States, where the regulatory pathway has been more complex. The synthetic form of Ta1 (thymalfasin) is manufactured through solid-phase peptide synthesis, ensuring consistency and purity.

ARA-290 / Cibinetide: Innate Repair Receptor Agonist

Origins and Structure

ARA-290, also known as Cibinetide, is a synthetic 11-amino-acid peptide designed to selectively activate the innate repair receptor (IRR), a heteromeric receptor complex composed of the erythropoietin receptor (EPOR) and the beta common receptor (βcR/CD131). This receptor was identified through research showing that erythropoietin (EPO), beyond its classical role in stimulating red blood cell production (erythropoiesis), also possesses tissue-protective and anti-inflammatory properties mediated through a distinct receptor complex.

The challenge with using EPO for tissue protection was that its erythropoietic activity — increasing red blood cell production — would cause polycythemia and thrombotic complications with chronic use. ARA-290 was designed to selectively activate the tissue-protective IRR pathway without stimulating erythropoiesis through the classical homodimeric EPO receptor.

Mechanism of Action

• Innate Repair Receptor Activation: ARA-290 binds to the EPOR/βcR heteromeric complex, triggering intracellular signaling cascades that promote cell survival, reduce apoptosis, and modulate inflammatory responses. This signaling pathway is distinct from the JAK2/STAT5 pathway primarily engaged by EPO at the homodimeric EPOR for erythropoiesis.
• Anti-Inflammatory Effects: ARA-290 has been shown to reduce the production of pro-inflammatory cytokines (including TNF-alpha, IL-1 beta, and IL-6) while promoting anti-inflammatory mediators. These effects are mediated through modulation of NF-kB signaling and other inflammatory pathways.
• Tissue Protection: In various preclinical models of tissue injury — including cardiac ischemia, renal injury, and spinal cord injury — ARA-290 has demonstrated cytoprotective effects, reducing tissue damage and improving functional outcomes.
• Nerve Repair: ARA-290 has shown particular promise in models of peripheral neuropathy, promoting nerve fiber regeneration and reducing neuropathic pain. The IRR is expressed on Schwann cells and sensory neurons, providing a direct mechanism for neurotrophic and neuroprotective effects.

Clinical Research

ARA-290 has advanced into human clinical trials, representing a more advanced stage of development than many peptides in this review:

• Sarcoidosis-Related Neuropathy: Clinical studies in patients with sarcoidosis-associated small fiber neuropathy have reported improvements in nerve fiber density (measured by corneal confocal microscopy), neuropathic pain scores, and quality of life measures following ARA-290 treatment.
• Diabetic Neuropathy: Studies in patients with type 2 diabetes and painful neuropathy have shown improvements in symptoms and evidence of nerve fiber regeneration.
• Metabolic Effects: Interestingly, some clinical studies have reported improvements in metabolic parameters including insulin sensitivity and hemoglobin A1c in diabetic patients, suggesting broader metabolic benefits beyond neuropathy.

The clinical program for ARA-290/Cibinetide has been conducted by Araim Pharmaceuticals. While results have been encouraging, the program has faced the typical challenges of clinical drug development, and the compound has not yet received regulatory approval in any major market.

Thymic Bioregulator Peptides: Thymalin and Thymagen

Thymalin

Thymalin is a peptide complex originally extracted from calf thymus glands, developed within the Russian bioregulatory peptide research framework associated with the Saint Petersburg Institute of Bioregulation and Gerontology. Unlike Thymosin Alpha-1, which is a single defined peptide, Thymalin was originally characterized as a mixture of low-molecular-weight thymic peptides, though specific active components have been identified in subsequent research.

The proposed mechanism of Thymalin involves regulation of immune system function through modulation of thymic activity. Research from the developing institution has reported effects including:

• Enhancement of T cell maturation and function
• Normalization of T cell subpopulations (CD4/CD8 ratios) in immunocompromised states
• Modulation of cytokine production
• Improvements in phagocytic cell function

Clinical studies conducted in Russia and former Soviet states have examined Thymalin in conditions including immunodeficiency states, chronic infections, post-surgical immune recovery, and age-related immune decline (immunosenescence). Some studies have reported notable outcomes, including a study in elderly populations that reported improved immune function and potentially extended lifespan, though these findings require cautious interpretation given study design limitations.

Thymalin has been used clinically in Russia and several former Soviet countries for decades but is not approved in Western markets.

Thymagen

Thymagen (Glu-Trp) is a synthetic dipeptide developed as a simplified, fully defined analog intended to capture the immunomodulatory activity of the Thymalin complex. As a bioregulator peptide from the Khavinson laboratory, Thymagen is proposed to act through the epigenetic/gene regulatory mechanism described for this class of compounds — directly interacting with DNA to modulate the expression of genes involved in immune cell function and thymic activity.

Research on Thymagen has reported immunostimulatory effects in cell culture and animal models, including enhanced T cell proliferation, improved immune cell function under stress conditions, and modulation of cytokine expression. Clinical studies in elderly subjects have reported improvements in immune parameters and general health indicators.

The same limitations that apply to the bioregulator peptide class generally also apply to Thymagen: the proposed direct peptide-DNA mechanism requires further independent validation, and the clinical evidence comes primarily from Russian institutions.

Crystagen: An Immune Bioregulator Peptide

Structure and Proposed Mechanism

Crystagen (Thr-Glu-Asp) is a synthetic tripeptide bioregulator from the Khavinson program, designed to target immune system function. Like other bioregulator peptides, Crystagen is proposed to modulate gene expression related to immune cell function through direct peptide-DNA interaction at the transcriptional level.

Research from the developing institution has investigated Crystagen's effects on various aspects of immune function:

• T Cell Function: Studies have reported that Crystagen can enhance T cell proliferation, cytokine production, and functional activity in cell culture models and in animal studies.
• Immune Recovery: In models of immunosuppression (including radiation-induced and chemotherapy-induced immunosuppression), Crystagen has been reported to accelerate immune recovery, with improvements in lymphocyte counts and functional immune parameters.
• Aging-Related Immune Decline: Research in elderly populations has examined Crystagen's potential to counteract immunosenescence, with some studies reporting improved immune function markers following treatment.
• Stress Resilience: Some studies have investigated Crystagen's effects on immune function under physiological stress conditions, reporting maintenance of immune competence in stressed animals.

Evidence Quality

Crystagen's evidence base shares the characteristics and limitations of the broader bioregulator peptide program. Published studies come primarily from the Khavinson research network, and international independent replication remains limited. The peptide has been used in research and clinical settings in Russia and some other countries but lacks Western regulatory approval.

Vilon: A Dipeptide Immune Bioregulator

Structure and Proposed Mechanism

Vilon (Lys-Glu) is one of the simplest bioregulator peptides in the Khavinson series — a dipeptide consisting of just two amino acids. Despite this molecular simplicity, Vilon has been the subject of substantial research within the bioregulator framework, with proposed effects on immune system function and potentially on lifespan.

The proposed mechanism follows the bioregulator paradigm: Vilon is theorized to interact with specific DNA sequences related to immune gene expression, modulating transcription in a way that supports immune cell function and development. The notion that a dipeptide could achieve such specific gene regulatory effects is perhaps the most challenging aspect of the bioregulator theory to reconcile with conventional molecular biology, as two amino acids provide very limited molecular surface area for specific DNA recognition.

Research Findings

Published research on Vilon has reported:

• Immune Enhancement: Cell culture and animal studies have reported that Vilon can stimulate lymphocyte proliferation, enhance T cell function, and improve immune cell viability under stress conditions.
• Gene Expression Effects: Studies examining gene expression changes following Vilon treatment have reported modulation of genes involved in immune function, cell cycle regulation, and stress response. These transcriptomic findings, if reproducible, suggest that even very short peptides can have measurable effects on cellular gene expression, though the mechanism may not necessarily involve direct DNA binding.
• Aging Research: Some of the most attention-grabbing research on Vilon has come from aging studies. A study in elderly subjects reported that Vilon treatment, combined with another bioregulator peptide (Epitalon), was associated with improved immune function markers and reduced mortality over a multi-year follow-up period. These findings generated significant interest but also significant scrutiny regarding study design and statistical analysis.
• Thymic Effects: Research has suggested that Vilon may support thymic function, potentially counteracting the age-related involution (shrinkage) of the thymus that contributes to immunosenescence in elderly individuals.

Critical Perspective

Vilon exemplifies both the intriguing potential and the substantial challenges of the bioregulator peptide field. The published findings, if validated by independent research, would suggest that even extremely simple peptide structures can have meaningful biological effects. However, the mechanism proposed (direct peptide-DNA interaction) remains scientifically controversial for dipeptides, and alternative explanations for observed effects — such as interactions with membrane receptors, intracellular signaling molecules, or metabolic pathways — have not been thoroughly excluded.

Comparative Analysis: Three Approaches to Immune Modulation

Antimicrobial Peptides (LL-37)

LL-37 represents the antimicrobial approach to immune modulation — a strategy rooted in the innate immune system's first line of defense. Its mechanism combines direct pathogen killing with immunomodulatory signaling, making it a dual-function molecule. The advantages of this approach include broad-spectrum antimicrobial activity, anti-biofilm effects, and the low likelihood of bacterial resistance development (compared to conventional antibiotics). The challenges include high production costs, potential cytotoxicity at high concentrations, and the complexity of managing a molecule with both pro-inflammatory and anti-inflammatory potential depending on context.

Defined Immunomodulatory Peptides (Thymosin Alpha-1, ARA-290)

Ta1 and ARA-290 represent the Western pharmaceutical approach to immune peptide development — single, well-characterized molecules with defined receptor targets, studied through conventional clinical trial methodology. Their advantages include well-understood mechanisms, reproducible manufacturing (solid-phase peptide synthesis), and clinical data generated to international regulatory standards. The evidence supporting their use is generally more robust and more accessible to international scientific review.

• Ta1 focuses on enhancing cellular immunity through dendritic cell and T cell activation, making it most relevant to conditions requiring stronger immune responses — chronic infections, cancer, and immunodeficiency.
• ARA-290 focuses on the tissue-protective arm of innate immunity, modulating inflammation and promoting repair without erythropoietic side effects. Its niche is in conditions where tissue damage and inflammation drive pathology — neuropathy, inflammatory diseases, and ischemic injury.

Bioregulatory Peptides (Thymalin, Thymagen, Crystagen, Vilon)

The bioregulatory peptides represent a distinctly different paradigm — very short peptides (2-4 amino acids) proposed to modulate gene expression directly. Their theoretical advantage is simplicity: small, stable, inexpensive to produce, and potentially orally bioavailable. If the proposed mechanisms are validated, they would represent a fundamentally new approach to pharmacology.

However, this approach currently faces the most significant evidence challenges:

• The proposed mechanism (direct peptide-DNA interaction) lacks a well-established biophysical basis for such short peptides
• Most evidence comes from a single research network, limiting the independent validation that is essential for scientific credibility
• Alternative mechanistic explanations have not been thoroughly explored
• Clinical studies generally do not meet the rigor expected by international regulatory agencies

Integration and Future Directions

The immune-modulating peptide field is evolving rapidly, driven by several converging trends:

• Antibiotic Resistance: The growing crisis of antibiotic-resistant bacteria has renewed interest in antimicrobial peptides like LL-37 as alternatives or adjuncts to conventional antibiotics.
• Cancer Immunotherapy: The success of immune checkpoint inhibitors and CAR-T cell therapy has created an environment receptive to immune-modulating agents like Ta1 that could enhance these approaches.
• Aging and Immunosenescence: As populations age globally, the need for safe immune-enhancing interventions in elderly populations has grown, driving research into peptides that could restore age-declined immune function.
• Precision Immunology: Advances in systems immunology and biomarker technology are enabling more precise characterization of how immune-modulating peptides affect different components of the immune system, moving beyond crude measures of "immune enhancement" to specific pathway-level understanding.

Each of the approaches reviewed here — antimicrobial, defined immunomodulatory, and bioregulatory — may ultimately find its place in the toolkit of immune modulation research. The key will be continued rigorous scientific investigation, independent replication of findings, and the translation of preclinical promise into validated clinical outcomes through well-designed trials.

This article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult qualified healthcare professionals regarding any health-related questions or decisions.